Set to start in 2025, Relay Therapeutics is moving toward a pivotal study of experimental treatment RLY-2608 in heavily ...

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...

Shares of Relay Therapeutics RLAY soared 52.4% on Sept. 9 after the company announced positive interim data from the ...

The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...

"It's appalling the way AstraZeneca has been treated. I wouldn't blame them if they were thoroughly fed up and decided to bow out of the Covid vaccine business." That was the view from one of the ...

AstraZeneca has started to move away from providing its Covid-19 vaccine to countries on a not-for-profit basis. The drugs giant has signed a series of for-profit agreements for next year, and ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...

LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...